As VDR expression was not different between Th17.1 cells from healthy controls and natalizumab-treated MS patients it can be expected that there are no differences in the responses of these cells to 1,25(OH2)D3 treatment as was shown previously for bulk CD4+ T cells (25). Here, VDR is linked to myeloid sarcoma.